Meeting
2022 ASCO Annual Meeting
Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function.
Authors
Omar Mamlouk
University of Texas MD Anderson Cancer Center, Department of Nephrology, Houston, TX
Omar Mamlouk , Paolo Strati , Lei Feng , Ryan Sun , Raphael Eric Steiner , Ranjit Nair , Christopher Flowers , Jeremy L Ramdial , Neeraj Saini , Samer Ali Srour , Richard E. Champlin , Partow Kebriaei , Loretta J. Nastoupil , Maria Alma Rodriguez , Elizabeth J. Shpall , Yago Nieto , Jason Westin , Sattva Swarup Neelapu , Sreedhar Mandayam , Sairah Ahmed
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7536)
DOI
10.1200/JCO.2022.40.16_suppl.7536
Abstract #
7536
Poster Bd #
189
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Patient perspectives on BCMA-targeted therapies for multiple myeloma: A survey conducted in a patient advocacy group.
First Author: Jennifer M. Ahlstrom
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Preclinical CAR-T cell target safety, biodistribution, and tumor infiltration analysis using in situ hybridization technology.
First Author: Helly Pimentel
Poster
2018 ASCO Annual Meeting
Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
First Author: Peihua Lu